Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yahoo finance add sls and review of the conversations tab.
you have a link ?
On yahoo they are talking 4 min.
Agree, might see 1.70’s again, worth the risk with a stop limit on shares purchased at 1$ or more
I believe it’s gonna before EOM… pr stated idmc scheduled ‘by’ EOM…
yup think next month data phase3 end april ... should see 1.50s before data
No way, lotto play here. This is nothing but risk
Let’s go $$$$$ reeling $$$$$$
Merry Christmas $$$$$
Doubt it, insiders just sold shares!
Rumor mill over on Stocktwits is that STELLAS is about to receive Orphan Drug status for their T-cell lymphoma treatment. No PR out yet but,.... Dated today,...
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=977523
Sex always makes money! Lol
SLS FDA NEWS WOOHOOOOOO WOOHOOOOOO
After that dilution it’l double in price, always does
Breakout coming, this science could be a game changer
Fingers crossed! Still an unknown, to us, but after the first IDMC & positive sentiment from Tuesday’s KOL TC it’s hard to imagine GPS not achieving its P3 primary endpoints!
3.09 trade! Lmao, mm’s will do anything to get cheapies. This ticker could be a huge play moving forwsrd $$$
“Following a prespecified review of unblinded data by the IDMC in accordance with its charter, its recommendation to continue the REGAL study as is, and with trial conduct and integrity intact, is outstanding news.” This quote was from the Sellas PR… does any know when the next ‘schedule’ IDMC review is? Or is that info not available to the public?
Wow glad we sold, held a few free ones, big hit today on the PR
Any thoughts here moving forward, still up over 100% from those lows a few weeks ago.
Sls looking good from 2$ range! $$$$
The update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) is on November 14, 2022.
The call will be facilitated by SELLAS management, including SELLAS' President and CEO, Angelos Stergiou, MD, ScD h.c., and Senior Vice President, Clinical Development, Dragan Cicic, MD, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee. Further details regarding how to access the update call will be provided in the coming weeks.
Phase 3 update call news. A flop?? Who knows
Ding ding ding we got a winner $$$$$$$$
Let it rain $$$$$$$$$
Wonderful time to load an just sit-on them, could be a 10 bagger with patience
Buy 20k wirth at 3.75 an u just made a quick 1500.00 flipping it in less than an hour! $$$$$
Trade it do not get married to this stock
That said, u can still make money on pumps an play the short position when needed.
Agree, they don't care about traders an investors. Management just takes their salaries an bonus' an class a shares an runs with it, its just how it is. Offer more shares, dilute, RS to clean everything up
These guys have been rampant with offerings since inception and reverse split and all rinse and repeat all the time.
Ouch! Might take a position here at these prices
C where she goes
Yeah we'l see. Positive buying today it seems
You take that back harry!!! I sure hope you are wrong with that prediction lol. I feel like SLS has HUGE potential and we will see a much higher PPS later this year. I might be wrong as well but only time will tell. Best of luck to you buddy :)
Followers
|
74
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2154
|
Created
|
07/20/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |